基于增强CT影像组学与多层感知机网络分类器预测胰腺导管腺癌CD20+B细胞表达
该研究纳入189例胰腺导管腺癌患者,从增强CT提取1409个影像组学特征,构建多层感知机网络分类器预测CD20+B淋巴细胞表达水平。模型在训练集AUC为0.82(95%CI 0.74-0.89),验证集AUC为0.84(95%CI 0.72-0.93),显示良好判别能力。高CD20+B表达患者生存期显著更长。
要点
- 增强CT影像组学联合MLP分类器可术前无创预测PDAC的CD20+B细胞表达状态。
- 模型验证集AUC达0.84,敏感度86.21%、特异度78.57%,具有较好判别效能。
- CD20+B高表达与更长生存相关,提示该影像标志物可能具有预后价值。
核心结论
- 基于增强CT的MLP网络分类器能准确预测PDAC患者CD20+B细胞表达水平。
研究设计与样本
- 回顾性研究纳入189例PDAC患者,训练集132例、验证集57例,均行免疫组化及影像组学特征提取。
- 使用X-tile软件将CD20+B淋巴细胞表达水平分为高表达组和低表达组。
- 从感兴趣体积中提取1409个影像组学特征,经方差分析和Spearman相关分析降维。
- 基于训练集和验证集开发多层感知机(MLP)网络分类器。
关键影像表现/征象
- 高CD20+B表达患者生存期显著长于低表达患者(log-rank检验)。
诊断标准与关键数值
- 训练集AUC 0.82(95%CI 0.74-0.89),敏感度92.42%、特异度57.58%、准确率0.75、阳性预测值0.69、阴性预测值0.88。
- 验证集AUC 0.84(95%CI 0.72-0.93),敏感度86.21%、特异度78.57%、准确率0.83、阳性预测值0.81、阴性预测值0.85。
临床应用与阅片要点
- 增强CT影像组学特征可作为术前预测PDAC免疫微环境的无创工具,辅助预后分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To develop and validate a machine-learning classifier based on contrast-enhanced computed tomography (CT) for the preoperative prediction of CD20+ B lymphocyte expression in patients with pancreatic ductal adenocarcinoma (PDAC).
METHODS: Overall, 189 patients with PDAC (n = 132 and n = 57 in the training and validation sets, respectively) underwent immunohistochemistry and radiomics feature extraction. The X-tile software was used to stratify them into groups with 'high' and 'low' CD20+ B lymphocyte expression levels. For each patient, 1409 radiomic features were extracted from volumes of interest and reduced using variance analysis and Spearman correlation analysis. A multilayer perceptron (MLP) network classifier was developed using the training and validation set. Model performance was determined by its discriminative ability, calibration, and clinical utility.
RESULTS: A log-rank test showed that the patients with high CD20+ B expression had significantly longer survival than those with low CD20+ B expression. The prediction model showed good discrimination in both the training and validation sets. For the training set, the area under the curve (AUC), sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were 0.82 (95% CI 0.74-0.89), 92.42%, 57.58%, 0.75, 0.69, and 0.88, respectively; whereas these values for the validation set were 0.84 (95% CI 0.72-0.93), 86.21%, 78.57%, 0.83, 0.81, and 0.85, respectively.
CONCLUSION: The MLP network classifier based on contrast-enhanced CT can accurately predict CD20+ B expression in patients with PDAC.
引用
- Yu J, Li Q, Zhang H, et al. Contrast-enhanced computed tomography radiomics and multilayer perceptron network classifier: an approach for predicting CD20+ B cells in patients with pancreatic ductal adenocarcinoma. Abdom Radiol (NY). 2021. PMID: 34708252. doi:10.1007/s00261-021-03285-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。